Hedalen

This research aims to evaluate a new approach to lowering ovarian cancer risk for women with high-risk genetic mutations such as BRCA1, BRCA2, RAD51C, RAD51D, and BRIP1. Traditional prevention involves removing both fallopian tubes and ovaries early, which reduces cancer risk but causes immediate menopause and other health issues. The study explores whether removing only the fallopian tubes first, with delayed removal of the ovaries later, is a safe alternative. Participants receive either a risk-reducing salpingectomy removal of fallopian tubes followed later by removal of the ovaries or the standard risk-reducing salpingo-oophorectomy removal of both tubes and ovaries at once. Timing for surgeries varies by genetic mutation and age ranges, for example, BRCA1 carriers may have the tubes removed between ages 25 and 40 and ovaries removed by age 45. The study compares these two strategies to assess safety and cancer incidence over time. Women enrolled in the study will undergo surgeries and will be monitored through follow-up visits including pathology checks six weeks after surgery and long-term tracking of ovarian, pelvic, and breast cancer incidence until age 70. The main outcome measured is the occurrence of high-grade serous ovarian cancer up to age 45 or 50, depending on mutation type. Safety, cancer occurrence, and surgery uptake are carefully recorded over many years, with participation possibly spanning decades.